These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 30921632)

  • 1. Elucidating the glutamatergic processes underlying mismatch negativity deficits in early stage bipolar disorder and schizophrenia: A combined
    Kaur M; Chitty KM; Lagopoulos J; Hickie IB; Duffy SL; Hermens DF
    J Psychiatr Res; 2019 Jun; 113():83-89. PubMed ID: 30921632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hippocampal glutamatergic/NMDA receptor functioning in bipolar disorder: A study combining mismatch negativity and proton magnetic resonance spectroscopy.
    Chitty KM; Lagopoulos J; Hickie IB; Hermens DF
    Psychiatry Res; 2015 Aug; 233(2):88-94. PubMed ID: 26070970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mismatch Negativity and Cortical Thickness in Patients With Schizophrenia and Bipolar Disorder.
    Kim S; Jeon H; Jang KI; Kim YW; Im CH; Lee SH
    Schizophr Bull; 2019 Mar; 45(2):425-435. PubMed ID: 29684224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A systematic review and meta-analysis of proton magnetic resonance spectroscopy and mismatch negativity in bipolar disorder.
    Chitty KM; Lagopoulos J; Lee RS; Hickie IB; Hermens DF
    Eur Neuropsychopharmacol; 2013 Nov; 23(11):1348-63. PubMed ID: 23968965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Longitudinal associations between mismatch negativity and disability in early schizophrenia- and affective-spectrum disorders.
    Kaur M; Lagopoulos J; Lee RS; Ward PB; Naismith SL; Hickie IB; Hermens DF
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Oct; 46():161-9. PubMed ID: 23851120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Choline Compounds of the Frontal Lobe and Temporal Glutamatergic System in Bipolar and Schizophrenia Proton Magnetic Resonance Spectroscopy Study.
    Galińska-Skok B; Małus A; Konarzewska B; Rogowska-Zach A; Milewski R; Tarasów E; Szulc A; Waszkiewicz N
    Dis Markers; 2018; 2018():3654894. PubMed ID: 30595760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurophysiological biomarkers support bipolar-spectrum disorders within psychosis cluster.
    Kaur M; Battisti RA; Lagopoulos J; Ward PB; Hickie IB; Hermens DF
    J Psychiatry Neurosci; 2012 Sep; 37(5):313-21. PubMed ID: 22469054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frontal Glutamate and γ-Aminobutyric Acid Levels and Their Associations With Mismatch Negativity and Digit Sequencing Task Performance in Schizophrenia.
    Rowland LM; Summerfelt A; Wijtenburg SA; Du X; Chiappelli JJ; Krishna N; West J; Muellerklein F; Kochunov P; Hong LE
    JAMA Psychiatry; 2016 Feb; 73(2):166-74. PubMed ID: 26720179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mismatch negativity/P3a complex in young people with psychiatric disorders: a cluster analysis.
    Kaur M; Lagopoulos J; Ward PB; Watson TL; Naismith SL; Hickie IB; Hermens DF
    PLoS One; 2012; 7(12):e51871. PubMed ID: 23251645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigating the role of glutathione in mismatch negativity: An insight into NMDA receptor disturbances in bipolar disorder.
    Chitty KM; Lagopoulos J; Hickie IB; Hermens DF
    Clin Neurophysiol; 2015 Jun; 126(6):1178-1184. PubMed ID: 25454340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mismatch negativity in bipolar disorder: A neurophysiological biomarker of intermediate effect?
    Hermens DF; Chitty KM; Kaur M
    Schizophr Res; 2018 Jan; 191():132-139. PubMed ID: 28450056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mismatch negativity in schizophrenia spectrum and bipolar disorders: Group and sex differences and associations with symptom severity.
    Pentz AB; Timpe CMF; Normann EM; Slapø NB; Melle I; Lagerberg TV; Steen NE; Westlye LT; Jönsson EG; Haukvik UK; Moberget T; Andreassen OA; Elvsåshagen T
    Schizophr Res; 2023 Nov; 261():80-93. PubMed ID: 37716205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Age, Antipsychotic Medication, and Symptom Severity in Schizophrenia With Proton Magnetic Resonance Spectroscopy Brain Glutamate Level: A Mega-analysis of Individual Participant-Level Data.
    Merritt K; McGuire PK; Egerton A; ; Aleman A; Block W; Bloemen OJN; Borgan F; Bustillo JR; Capizzano AA; Coughlin JM; De la Fuente-Sandoval C; Demjaha A; Dempster K; Do KQ; Du F; Falkai P; Galinska-Skok B; Gallinat J; Gasparovic C; Ginestet CE; Goto N; Graff-Guerrero A; Ho BC; Howes OD; Jauhar S; Jeon P; Kato T; Kaufmann CA; Kegeles LS; Keshavan M; Kim SY; Kunugi H; Lauriello J; Liemburg EJ; Mcilwain ME; Modinos G; Mouchlianitis ED; Nakamura J; Nenadic I; Öngür D; Ota M; Palaniyappan L; Pantelis C; Plitman E; Posporelis S; Purdon SE; Reichenbach JR; Renshaw PF; Russell BR; Sawa A; Schaefer M; Shungu DC; Smesny S; Stanley JA; Stone JM; Szulc A; Taylor R; Thakkar K; Théberge J; Tibbo PG; van Amelsvoort T; Walecki J; Williamson PC; Wood SJ; Xin L; Yamasue H
    JAMA Psychiatry; 2021 Jun; 78(6):667-681. PubMed ID: 33881460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Similarities of biochemical abnormalities between major depressive disorder and bipolar depression: a proton magnetic resonance spectroscopy study.
    Zhong S; Wang Y; Zhao G; Xiang Q; Ling X; Liu S; Huang L; Jia Y
    J Affect Disord; 2014 Oct; 168():380-6. PubMed ID: 25106035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progressive and interrelated functional and structural evidence of post-onset brain reduction in schizophrenia.
    Salisbury DF; Kuroki N; Kasai K; Shenton ME; McCarley RW
    Arch Gen Psychiatry; 2007 May; 64(5):521-9. PubMed ID: 17485604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Associations of mismatch negativity with psychotic symptoms and functioning transdiagnostically across psychotic disorders.
    Donaldson KR; Novak KD; Foti D; Marder M; Perlman G; Kotov R; Mohanty A
    J Abnorm Psychol; 2020 Aug; 129(6):570-580. PubMed ID: 32757601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How specific are deficits in mismatch negativity generation to schizophrenia?
    Umbricht D; Koller R; Schmid L; Skrabo A; Grübel C; Huber T; Stassen H
    Biol Psychiatry; 2003 Jun; 53(12):1120-31. PubMed ID: 12814863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Attenuated mismatch negativity in patients with first-episode antipsychotic-naive schizophrenia using a source-resolved method.
    Randau M; Oranje B; Miyakoshi M; Makeig S; Fagerlund B; Glenthøj B; Bak N
    Neuroimage Clin; 2019; 22():101760. PubMed ID: 30927608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resting-state glutamatergic neurotransmission is related to the peak latency of the auditory mismatch negativity (MMN) for duration deviants: An (1)H-MRS-EEG study.
    Kompus K; Westerhausen R; Craven AR; Kreegipuu K; Põldver N; Passow S; Specht K; Hugdahl K; Näätänen R
    Psychophysiology; 2015 Sep; 52(9):1131-9. PubMed ID: 25917405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The relationship between synaptic density marker SV2A, glutamate and N-acetyl aspartate levels in healthy volunteers and schizophrenia: a multimodal PET and magnetic resonance spectroscopy brain imaging study.
    Onwordi EC; Whitehurst T; Mansur A; Statton B; Berry A; Quinlan M; O'Regan DP; Rogdaki M; Marques TR; Rabiner EA; Gunn RN; Vernon AC; Natesan S; Howes OD
    Transl Psychiatry; 2021 Jul; 11(1):393. PubMed ID: 34282130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.